Overview

Prospective Study of End Stage Renal Disease Patients With Coronary Artery Disease Treated by Oral Nicorandil

Status:
Active, not recruiting

Trial end date:
2021-12-01

Target enrollment:
0

Participant gender:
All

Summary

Nicorandil is potentially effective to prevent cardiovascular events in patients with coronary artery disease (CAD) receiving hemodialysis. The purpose of this study is to prospectively investigate whether nicorandil is effective in reducing the incidence of cardiovascular events in patients with CAD on hemodialysis.

Phase:

Phase 4

Accepts Healthy Volunteers?

Details

Lead Sponsor:

Kumamoto University

Treatments:

Nicorandil

Criteria

Inclusion Criteria:

Eligible patients are who meet the following criteria:

- Patient with previously diagnosed coronary artery disease (significant coronary artery
stenosis is defined as > 75% narrowing of the artery lumen)

- Patients who continued hemodialysis for more than one month

Exclusion Criteria:

- Within one month after acute myocardial infarction

- Within 3 months after coronary artery bypass graft (CABG)

- Treatment with phosphodiesterase type 5 inhibitor

- Candidates for carotid artery stenting

- Severe disease requiring active medical treatment